Vanderbilt University anti-inflammatory therapy licensed to Amytrx is now in clinical trials for eczema treatment
Oct. 27, 2020—Jacek Hawiger’s anti-inflammatory peptide therapy, licensed by Amytrx and now in clinical trials, has the potential to safely and effectively treat a multitude of inflammatory and metabolic diseases.
Jul. 30, 2020—A protein linked to amyotrophic lateral sclerosis (ALS), a progressive neurological disease that causes muscle weakness, may be a key to treating fibrotic disease of the kidneys and other organs, researchers at Vanderbilt University Medical Center reported recently.
Nov. 5, 2019—A novel tool developed by Vanderbilt scientists protects animals from endotoxin shock and can be used for mechanistic analyses of inflammation due to microbial and other insults.
May. 24, 2018—During Wednesday’s Spring Faculty Meeting, Jeff Balser, M.D., Ph.D., dean of Vanderbilt University School of Medicine and President and CEO of Vanderbilt University Medical Center, highlighted the medical school’s rising stature among the country’s top-tier institutions.
Jun. 22, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have found a way to calm the “genomic storm” that triggers the often-lethal consequences of sepsis.
Jun. 1, 2017—The 3rd National Veterans Health Affairs Research Conference held at Vanderbilt University Medical Center May 17-18.
Dec. 9, 2016—Vanderbilt investigators have discovered how a promising cancer immunotherapy causes brain swelling, findings that could lead to ways to protect brain function while fighting cancers.
Nov. 25, 2016—Nine Vanderbilt University faculty members have been elected fellows of the American Association for the Advancement of Science this year.
Oct. 28, 2014—A cell-penetrating peptide developed at Vanderbilt blocks the signaling pathways that lead to lethal shock caused by bacterial infection.
Aug. 1, 2014—Vanderbilt researchers have discovered that the protein CRADD counteracts inflammatory injury to endothelial cells, which could assist the development of new therapies for inflammatory vascular disorders.
Oct. 11, 2013—Importin alpha 5, a member of a family of proteins that “shuttle” other proteins into the nucleus, is a potential new target for drugs to treat inflammatory diseases.
Aug. 8, 2013—The protein SARM appears to protect cells from inflammation-driven death by stabilizing the nuclear laminin scaffold.